China's Cellular Biomedicine spikes on early CAR-T data

Shanghai drug developer Cellular Biomedicine ($CBMG) reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday. The company, working alongside Chinese PLA General Hospital, is developing an engineered T cell therapy, or CAR-T, to treat Hodgkin's lymphoma. In a trial on 7 patients with late-stage lymphoma, the treatment stabilized the disease in three subjects and charted a partial response in two of them, Cellular Biomedicine said. Release